image goes here
Preparing for Multisite Gene Therapy Studies
The dramatic growth of the gene therapy is unprecedented, as the U.S. Food and Drug Administration (FDA) and other international regulatory agencies have begun issuing approvals for licensed gene therapy products.
The field is growing particularly fast in oncology, infectious diseases, and diseases caused by a single defective gene. For human gene transfer studies that receive federal funds or take place at sites receiving federal funds, federal requirements call for both institutional review board (IRB) and institutional biosafety committee (IBC) review.
In this webinar, you’ll learn the basics of preparing for gene therapy research and the IBC’s role in ensuring safe and responsible research.
Learning Objectives
Following this webinar, attendees will be able to:
- Define federal requirements and oversight structure governing gene therapy research involving recombinant DNA and synthetic nucleic acid technology
- Explain the role and functions of the IBC, including types of studies requiring IBC review
- Describe how to prepare for IBC review
- Identify the benefits of centralized IBC review of multisite gene therapy studies
Learning Objectives
Following this free webinar, attendees will be able to:
- Define the federal requirements and oversight structure governing gene therapy research involving recombinant DNA and synthetic nucleic acid technology
- Explain the role and functions of the IBC, including types of studies which may require IBC review
- Describe how to prepare for IBC review
- Identify the benefits of centralized review of multisite gene therapy studies through externally administered IBCs
Presented By
Daniel Eisenman
PhD, RBP, SM (NRCM), CBSP
Director of Biosafety Services
Advarra
Not in use
Not in use
Not in use
Not in use
Duration: 1 hour